Home › Cancro al seno › Texas › League City
Studi clinici su Cancro al seno a League City, TX
12 studi su Cancro al seno cercano partecipanti presso sedi a League City e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
In reclutamentoFase 1
- NEXT Houston, Galveston · a 23 mi di distanza
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
In reclutamentoFase 3
- Tranquility Research, Webster · a 3 mi di distanza
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
In reclutamentoFase 3
- Tranquil Clinical Research, Webster · a 3 mi di distanza
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
In reclutamentoFase 3
- UT MD Anderson - League City, League City
- Houston Methodist Saint John Hospital, Nassau Bay · a 3 mi di distanza
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
In reclutamentoFase 2
- Tranquil Clinical Research, Webster · a 3 mi di distanza
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
In reclutamentoFase 1
- The University of Texas, MD Anderson Cancer Center - League City, League City
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
In reclutamentoFase 3
- MD Anderson League City, League City
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
In reclutamentoFase 3
- MD Anderson League City, League City
- Houston Methodist Saint John Hospital, Nassau Bay · a 3 mi di distanza
- University of Texas Medical Branch, Galveston · a 23 mi di distanza
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
In reclutamentoStudio osservazionale
- MD Anderson League City, Nassau Bay · a 3 mi di distanza
Feasibility Study for the SIRA-1000, SIRA® RFA Electrosurgical Device as an Adjunct to Breast Conserving Surgery
In reclutamento
- University of Texas Medical Branch at Galveston, TX, Galveston · a 23 mi di distanza
THRIVE Well Cancer FDTN/Exercise_Creatine Supplementation
In reclutamentoVolontari sani benvenuti
- The University of Texas Medical Branch, Galveston, Galveston · a 23 mi di distanza
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
In reclutamentoStudio osservazionale
- University of Texas Medical Branch, League City
- Texas Oncology - Webster, Webster · a 3 mi di distanza
Studi su Cancro al seno in altre città
- New York City, NY136 studi
- Houston, TX126 studi
- Boston, MA112 studi
- Nashville, TN81 studi
- Los Angeles, CA73 studi
- Edison, NJ68 studi
- St. Louis, MO64 studi
- Queens, NY64 studi
- Durham, NC64 studi
- Chicago, IL59 studi
- Philadelphia, PA56 studi
- Dallas, TX55 studi
Altri studi a League City
- Cancro del polmone non a piccole cellule15 studi
- Cancro metastatico7 studi
- Colite ulcerosa6 studi
- Cancro ai polmoni6 studi
- Cancro colorettale6 studi
- Cancro (tutti i tipi)5 studi
- Cancro ovarico5 studi
- Ictus5 studi
- Cancro della vescica4 studi
- Carcinoma a cellule squamose della testa e del collo4 studi
- Cancro alla prostata4 studi
- Condizioni post-COVID (Long COVID)3 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.